Celldex Therapeutics
CLDX
135 hedge funds and large institutions have $1.31B invested in Celldex Therapeutics in 2014 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 52 increasing their positions, 43 reducing their positions, and 37 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 43
5% less capital invested
Capital invested by funds: $1.38B → $1.31B (-$67.4M)
14% less funds holding
Funds holding: 157 → 135 (-22)
50% less call options, than puts
Call options by funds: $16.9M | Put options by funds: $33.9M
57% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
+$45.3M |
| 2 |
Bank of New York Mellon
New York
|
+$27.4M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$19.8M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$18.4M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$13.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$24.9M |
| 2 |
BLM
Bennett Lawrence Management
New York
|
-$15.4M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$15.3M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$9.44M |
| 5 |
CCI
Columbus Circle Investors
|
-$5.51M |
CLDX Hedge Fund Activity: Q2 2014 in Review
135 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q2 2014, worth a combined $1.31B — down 4.9% from $1.38B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of CLDX and 16 opened new positions — a net loss of 21 holders — while 43 trimmed existing stakes and 52 added.
The largest buyer was OppenheimerFunds, adding an estimated $45.3M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $24.9M sold.
- 135 institutional investors held Celldex Therapeutics (CLDX) as of Q2 2014, down from 157 in Q1 2014.
- Funds reported $1.31B of Celldex Therapeutics stock for Q2 2014, down 4.9% quarter-over-quarter.
- 16 funds opened new Celldex Therapeutics positions in Q2 2014 and 37 closed out, a net change of -21 holders.
- The largest Celldex Therapeutics buyer in Q2 2014 was OppenheimerFunds, an estimated $45.3M added.
- The largest Celldex Therapeutics seller in Q2 2014 was Sectoral Asset Management, an estimated $24.9M sold.
Based on aggregated 13F filings for Q2 2014.